(Q67776563)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1749294%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

review article

1 reference

title

The fluoroquinolones (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1749294%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

The Fluoroquinolones (English)

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)62477-X

15 November 2022

author name string

R. C. Walker

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1749294

15 November 2022

A. J. Wright

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1749294

15 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1749294

15 November 2022

publication date

1 December 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1749294%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

17 September 2019

https://api.elsevier.com/content/article/PII:S002561961262477X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)62477-X

https://api.elsevier.com/content/article/PII:S002561961262477X?httpAccept=text/plain

15 November 2022

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)62477-X

15 November 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1749294%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

volume

66

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1749294%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

page(s)

1249-1259

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1749294%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1749294%20AND%20SRC:MED&resulttype=core&format=json

Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections

17 September 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Increasing resistance of Staphylococcus aureus to ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Emerging resistance to fluoroquinolones in staphylococci: an alert

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Fluoroquinolone antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Fluoroquinolone antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Structure-activity relationships of the fluoroquinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Bacterial resistance to quinolones: mechanisms and clinical importance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Plasmid-mediated 4-quinolone resistance: a real or apparent absence?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Inhibition of norfloxacin absorption by antacids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Sucralfate significantly reduces ciprofloxacin concentrations in serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Theophylline dosage adjustment during enoxacin coadministration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Effects of enoxacin on renal and metabolic clearance of theophylline in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Safety of fleroxacin coadministered with theophylline to young and elderly volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections. The Urinary Tract Infection Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Comparison of ofloxacin and ceftriaxone in the treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Failure of norfloxacin to eradicate Chlamydia trachomatis in nongonococcal urethritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Dose-ranging study of fleroxacin for treatment of uncomplicated Chlamydia trachomatis genital infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Ciprofloxacin compared with doxycycline for nongonococcal urethritis. Ineffectiveness against Chlamydia trachomatis due to relapsing infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Use of norfloxacin to treat chronic typhoid carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Ciprofloxacin for Salmonella bacteremia in the acquired immunodeficiency syndrome (AIDS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Use of the new quinolones in cystic fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Ofloxacin versus parenteral therapy for chronic osteomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Successful treatment of malignant external otitis with oral ciprofloxacin: report of experience with 23 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Pefloxacin treatment of meningitis caused by gram-negative bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Evaluation of single-dose ciprofloxacin in the eradication of Neisseria meningitidis from nasopharyngeal carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Specific toxicologic aspects of the quinolones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Adverse effects of the fluoroquinolones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Serum sickness-like illness associated with ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Anaphylactoid reactions reported after treatment with ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Inappropriate use of oral ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

Use of quinolones in chlamydial infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

7 January 2021

Synergy of fluoroquinolones with other antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

7 January 2021

Metabolism of gyrase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

7 January 2021

Drug interactions with quinolones.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

7 January 2021

Comparative studies of fluoroquinolones in the treatment of urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

7 January 2021

Impact of fluoroquinolones on the gastrointestinal flora

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

7 January 2021

Prevention of infections in granulocytopenic patients by fluorinated quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

7 January 2021

Use of quinolones for the treatment of patients with bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

7 January 2021

Quinolones in the treatment of lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

7 January 2021

Quinolone therapy for infections of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

7 January 2021

Long-term use of quinolones and their safety

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2962477-X

7 January 2021

Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule

series ordinal

22

1 reference

https://api.crossref.org/works/10.1016/S0025-6196(12)62477-X

15 November 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1749294%20AND%20SRC:MED&resulttype=core&format=json

17 September 2019

1 reference